Bridgefront Capital LLC Purchases 11,315 Shares of Bristol Myers Squibb Company $BMY

Bridgefront Capital LLC increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 51.2% in the third quarter, Holdings Channel reports. The fund owned 33,404 shares of the biopharmaceutical company’s stock after purchasing an additional 11,315 shares during the quarter. Bridgefront Capital LLC’s holdings in Bristol Myers Squibb were worth $1,507,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Harbor Capital Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares during the period. Total Investment Management Inc. bought a new position in shares of Bristol Myers Squibb during the second quarter valued at approximately $38,000. Twin Peaks Wealth Advisors LLC purchased a new position in Bristol Myers Squibb during the second quarter valued at approximately $40,000. Finally, Bank of Jackson Hole Trust increased its holdings in Bristol Myers Squibb by 352.2% during the third quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 810 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Price Performance

NYSE BMY opened at $59.02 on Friday. The firm’s fifty day simple moving average is $58.24 and its two-hundred day simple moving average is $51.43. The firm has a market capitalization of $120.18 billion, a P/E ratio of 17.11, a P/E/G ratio of 0.17 and a beta of 0.26. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The business had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a $0.63 dividend. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of analyst reports. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a report on Wednesday, December 3rd. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 price target on shares of Bristol Myers Squibb in a report on Friday, February 6th. Citigroup upped their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Leerink Partners raised their price objective on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Nine analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $61.00.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.